title: Experimental otitis media with effusion induced by platelet activating factor.
abstract: This study tested the hypothesis that platelet activating factor (PAF) in the middle ear can induce otitis media with effusion (OME) and that PAF antagonists can prevent PAF-induced OME. An initial trial of 16 micrograms of PAF was injected into chinchilla bullae, and all ears developed middle ear effusion (MEE) within 48 hours. Subsequent trials were performed to test dose dependency. Interestingly, 1 or 16 micrograms of PAF caused more MEE and inflammation than did 4 or 8 micrograms. A dose of 0.5 micrograms PAF did not cause MEE. Middle ear effusion from injected bullae contained the full spectrum of lipoxygenase and cyclooxygenase products; additionally, more PAF was detected than was injected. Finally, a PAF antagonist (WEB 2170) injected intraperitoneally prevented PAF-induced OME. This study demonstrates that PAF injected into the middle ear can induce OME and that PAF antagonists effectively prevent PAF-induced OME. These findings suggest that PAF plays an important role in the pathogenesis of OME.
authors.affiliation: Division of Otolaryngology-Head and Neck Surgery, Loma Linda University School of Medicine, California.
authors.forename: C K
authors.initials: CK
authors.lastname: Rhee
authors.forename: T T
authors.initials: TT
authors.lastname: Jung
authors.forename: S
authors.initials: S
authors.lastname: Miller
authors.forename: D
authors.initials: D
authors.lastname: Weeks
mesh_terms: D000818:Animals; D001381:Azepines / Q000627:therapeutic use; D002682:Chinchilla; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D010034:Otitis Media with Effusion / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control; D010972:Platelet Activating Factor / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D013701:Temporal Bone / Q000473:pathology; D013997:Time Factors; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D001381:Azepines; D010972:Platelet Activating Factor; D014230:Triazoles; C063964:bepafant